1083-CRISPRa Mapping of Cancer Glycome and Immune Evasion

This study utilizes CRISPR activation (CRISPRa) screening to identify the genetic drivers behind cancer glycome remodeling, a process where tumors alter their surface sugars to evade the immune system. By forcing the overexpression of thousands of genes, the researchers mapped how specific enzymes and "professional ligands" like CD44 and CSPG4 facilitate binding to inhibitory Siglec receptors on immune cells. Their findings reveal that Siglec-10 primarily interacts with N-linked sialoglycans rather than exclusively binding to CD24, as previously thought. The study also highlights the sulfotransferase GAL3ST4 as a significant promoter of immune evasion and a poor prognostic marker in glioma patients. Ultimately, this research provides a comprehensive genomic atlas of cancer-associated glycosylation, offering new targets for anticancer immunotherapy.

References:

• Daly J, Piatnitca L, Al-Seragi M, et al. CRISPR activation screens map the genomic landscape of cancer glycome remodeling[J]. Cell Genomics, 2026, 6(4).